Lepu Biotechnology Co., Ltd. is an innovative biopharmaceutical enterprise based in China and facing the world, focusing on the field of tumor treatment.
The company has developed a strong product channel, focusing on tumor candidate drugs, including ADC, oncolytic drugs and immunotherapy in clinical and preclinical stages. Anti-PD- 1 and anti-PD-L 1 candidate drugs are the cornerstone of the company's immunotherapy and the pillar of the company's assembly line. It is planned to realize the domestic commercialization of the product pipeline by establishing a professional sales and marketing team, and push the product pipeline to overseas markets such as the United States and Europe through cooperation with overseas enterprises.
As of April, 2002 1 21year, all products of the company are still in the research and development stage, and the production activities are mainly to produce clinical materials supporting clinical trials. The company is building production facilities in Shanghai Biological Park. The total design capacity of Shanghai Phase I project is 12000 L, and a production line with a capacity of 6,000L is under construction.